NCT03734029: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
- State
- Completed
- Phase
- Phase 3
- People
- 557 taking part
- Started
- 27 Dec 2018
- Primary completion
- 11 Jan 2022
- Arms
- Trastuzumab deruxtecan
- Results
- Posted on the registry
- Papers
- doi:10.1007/s12282-024-01600-7, doi:10.1016/j.annonc.2023.08.003, doi:10.1016/j.critrevonc.2024.104305, doi:10.1038/s41591-025-03981-4, doi:10.1056/nejmoa2203690, doi:10.1093/oncolo/oyaf048, doi:10.1155/tbj/7212120, doi:10.1200/jco.22.02447, doi:10.1200/op.22.00480
- 7 Nov 2018: Trial registered
- 27 Dec 2018: Trial started
- 15 Jun 2023: Trial results posted
- 19 May 2026: Trial completed